華海藥業(600521.SH)逆勢漲超4% 意大利傳染病診所或將開始使用注射用瑞德西韋
格隆匯3月17日丨早盤一度下跌超4%的華海藥業(600521.SH)今日整體呈震盪走高態勢,臨近尾盤一度出現小幅拉昇漲超5%,今日盤中振幅達10.43%,最終收漲4.73%報21.48元,成交10.53億元,最新總市值284億元。據意大利當地媒體3月13日報道,醫院傳染病診所將很快開始使用一種實驗藥物注射用瑞德西韋(Remdesivir),為治療Covid-19的患者打開了新希望。而當地媒體報道用的圖顯示是華海藥業的注射用瑞德西韋(供臨牀研究用)。針對意大利當地媒體的這一報道,華海藥業並沒有正面迴應,只稱具體以公司公告為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.